Age-related cognitive decline and neurodegeneration involve synaptic loss, tau pathology, amyloid accumulation, neuroinflammation, and declining BDNF and acetylcholine signaling. Peptide research in this area aims to promote new synaptogenesis, reduce neuroinflammation, restore neurotrophic factor levels, and protect against further neuronal loss.
1. Dihexa — Synaptogenesis / Neural Connectivity
Dihexa is an angiotensin IV analog developed by Washington State University researchers specifically for cognitive enhancement. It is estimated to be up to 10 million times more potent than BDNF at promoting synaptogenesis — the formation of new neural connections — and has shown dramatic reversal of cognitive deficits in Alzheimer’s animal models.
Dosing Protocol: 10–15 mg oral daily (compounded capsule), or 1–3 mg SubQ. Cycle: 4–8 weeks. Allow washout before repeating due to persistent structural effects.
2. Semax — BDNF Upregulation / Neuroprotection
Semax upregulates BDNF, NGF (nerve growth factor), and VEGF in the brain — three neurotrophic factors dramatically reduced in cognitive decline. It enhances dopaminergic tone, improves cerebral blood flow, and has demonstrated neuroprotective effects against ischemia and neurotoxic insults.
Dosing Protocol: 300–600 mcg intranasal daily (split AM/midday). SubQ: 300–500 mcg daily. Cycle 10 days on / 5 days off for extended use.
3. Epithalon — Telomere / Pineal Regulation
Aging of the pineal gland drives disruption of circadian cortisol and melatonin cycles — accelerating neurodegeneration. Epithalon restores pineal function, lengthens telomeres in neuronal cells, and has demonstrated improvements in age-related memory markers and longevity in multiple studies.
Dosing Protocol: 5–10 mg SubQ daily for 10-day courses. 2x per year. Some researchers extend to 20-day courses for established cognitive decline.
4. Cerebrolysin — Neuropeptide Mix / Alzheimer’s Research
Cerebrolysin is a standardized mixture of neuropeptides and amino acids derived from pig brain proteins, approved in multiple countries for Alzheimer’s disease and stroke recovery. It provides a cocktail of low-molecular-weight neurotrophic peptides that penetrate the BBB and directly support neuronal survival, plasticity, and cholinergic function.
Dosing Protocol: 5–10 mL IV or IM daily for 20-day courses. Lower doses (2–5 mL IM) used for maintenance. Typically administered in clinical settings.
Dihexa builds new synaptic architecture while Semax maintains the BDNF and cerebral blood flow needed to sustain those connections. Epithalon addresses the pineal aging that accelerates the neuroendocrine decline driving cognitive deterioration. Cerebrolysin provides a comprehensive neuropeptide support mixture that directly nurtures surviving neurons and promotes recovery of damaged circuits.
- McCoy MK et al. (2012). Dihexa and cognitive function. Sci Transl Med.
- Eremin KO et al. (2012). Semax BDNF and neuroprotection. Biochemistry (Moscow).
- Khavinson VKh et al. (2003). Epithalon telomere effects. Neuroendocrinology Letters.
- Alvarez XA et al. (2006). Cerebrolysin in Alzheimer’s disease. Ann Neurol. DOI: 10.1002/ana.20271
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).